We highlight subsite-specific effects, such as rectal cancer risk linked to LAMC1, a clinically actionable drug target, and identify CCM2 expression as a female-specific CRC risk factor involved in progesterone signalling. Here, LAMC1 is linked to colorectal carcinoma.